Plain-English translation of NCT05098210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called a personalized neo-antigen peptide vaccine combined with , an immunotherapy drug. The vaccine is customized for each patient based on their own tumor's unique characteristics. You would receive the vaccine along with , plus another medication called to help boost your immune system's response.
Some patients with advanced breast cancer, melanoma, or lung cancer don't respond well to standard immunotherapy alone. This trial is exploring whether adding a personalized vaccine can help your immune system better recognize and fight your cancer.
You likely qualify if…
You likely don't qualify if…
You would start by receiving injections of weekly, then begin the personalized vaccine injections every 4 weeks along with infusions every 2–4 weeks. This main treatment phase lasts 25 weeks, and you may be able to repeat it for another 6 months if you're benefiting. You would then continue alone for up to 12 months. Throughout the study, you'll have blood draws, tumor biopsies, and imaging scans (CT or PET) to monitor how you're responding. Follow-up visits continue for up to a year after treatment ends.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States